XHEL
REG1V
Market cap417mUSD
Jun 18, Last price
12.52EUR
1D
-1.26%
1Q
-31.13%
Jan 2017
23.23%
IPO
2,109.40%
Name
Revenio Group Oyj
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Founded in 2001 and headquartered in Vantaa, Finland, Revenio Group Oyj operates as a health technology firm. This company specializes in developing, manufacturing, and distributing advanced ophthalmic diagnostic equipment and devices. These solutions are crucial for identifying and managing prevalent eye conditions such as glaucoma, macular degeneration, diabetic retinopathy, and cataracts, serving clients in Finland, across Europe, and worldwide. Their comprehensive product portfolio includes the iCare IC100 and IC200 tonometers, alongside the iCare HOME, an innovative device enabling patients to self-monitor their eye pressure. For advanced imaging, Revenio provides the iCare EIDON AF, which delivers confocal retinal imaging; the DRSplus, specifically designed for the detection of diabetic retinopathy; the iCare MAIA, a microperimeter used for precise visual field measurement; and the iCare COMPASS, facilitating fundus perimetry coupled with true-color confocal retinal images. Beyond hardware, the company also offers Oculo, a sophisticated eye care software platform. This platform seamlessly integrates functionalities for clinical communication, telehealth services, remote patient monitoring, and sophisticated data analytics.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||